Compare Cardinal Health Inc (CAH) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cardinal Health Inc vs Verisign, Inc. — how do they compare? Cardinal Health Inc trades at $228.88 (market cap $53.89B), while Verisign, Inc. trades at $268.98 (market cap $24.47B). The key difference: Cardinal Health Inc is far larger — about 2.2× Verisign, Inc.'s market cap, and Verisign, Inc. pays the higher dividend (1.21%). Which is the better fit depends on your goals.
| CAH | VRSN | |
|---|---|---|
Market Cap | $53.89B | $24.47B |
Sector | Health | Technology |
52-Week High | $239.71 | $310.00 |
52-Week Low | $146.04 | $211.49 |
Enterprise Value | $58.87B | $25.70B |
Dividend Yield | 0.89% | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cardinal Health (CAH) trades at $233.66, down 0.91% in the last session, with a bullish technical signal from moving averages and strong analyst support. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $3.17 surpassing expectations. Revenue reached $222.58 billion in 2025, though net margins remain thin at 0.62%. Recent news highlights growth potential in medical supplies, with earnings results for fiscal 2026 due August 11.
The outlook for CAH is positive, driven by earnings momentum and sector tailwinds, but risks include high leverage with debt-to-asset ratio at 16.09% and competitive pressures. Analyst consensus is bullish with a $248 price target, suggesting 6% upside. Investors should weigh solid operational cash flow against negative shareholder equity and investing outflows.
VeriSign (VRSN) trades at $270.31, up 0.07% with a bullish technical outlook. The stock shows strong fundamentals with 2025 revenue of $1.66B, net income of $825.7M, and exceptional 49.96% net margin. Recent Q1 2026 earnings beat expectations at $2.34 EPS. Analyst consensus is bullish with 57% buy ratings and $327.67 price target, representing 21% upside potential. The company maintains its monopoly position in .com/.net domain registry with predictable revenue growth.
VRSN presents a compelling investment case with stable cash flows and dominant market position, though trading at premium valuations (P/E 29.87). Key risks include contract renewals, AI disruption potential, and high debt levels. The upcoming Q2 2026 earnings report on July 23 will be critical for validating growth trajectory. Current levels offer attractive entry for long-term investors seeking defensive tech exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cardinal Health Inc
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
